Search Results - "Levy, Gweneth"

S722 Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Active Ulcerative Colitis Receiving 16 Weeks Extended Induction Treatment Followed by 52 Weeks Maintenance Treatment in U-ACHIEVE/U-ACCOMPLISH Trials by Panaccione, Remo, Danese, Silvio, Zhou, Wen, Klaff, Justin, Ilo, Dapo, Yao, Xuan, Levy, Gweneth, Higgins, Peter D., Loftus, Edward V., Vermeire, Séverine

Get full text

S777 Benefit–Risk Assessment of Upadacitinib Treatment in Patients With Moderately to Severely Active Ulcerative Colitis by Panaccione, Remo, Blumenstein, Irina, Irving, Peter, Vladea, Ramona, Ilo, Dapo, Zhou, Wen, Levy, Gweneth, Yao, Xuan, Dotan, Iris

Get full text

Pharmacokinetics, Safety, Tolerability, and Exploratory Efficacy of Upadacitinib in Children with Severe Atopic Dermatitis by Qian, Yuli, Raymundo, Eliza M., Hao, Shuai, Unnebrink, Kristina, Levy, Gweneth F., Teixeira, Henrique D., Chu, Alvina D., Zinn, Zachary A., Paller, Amy S., Liu, Wei, Mohamed, Mohamed-Eslam F.

“…•Upadacitinib was evaluated in children with moderate to severe atopic dermatitis.•Apparent oral clearance of upadacitinib was associated with pediatric body…”
Get full text

S1193 Safety of Upadacitinib in IBD: Pooled Analysis of Phase 3 Maintenance Studies, U-ACHIEVE and U-ENDURE, In Patients With Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease by Panaccione, Remo, Panés, Julian, Peyrin-Biroulet, Laurent, Colombel, Jean-Frederic, Lindsay, James, Baert, Filip, Atreya, Raja, Lacerda, Ana P., Park, Caroline, Anyanwu, Samuel I., Klaff, Justin, Liu, Jianzhong, Levy, Gweneth, Duncan, Benjamin, Vladea, Ramona, Rubin, David T.

Get full text

Pharmacokinetics, safety, and efficacy of cedirogant from phase I studies in healthy participants and patients with chronic plaque psoriasis by Mohamed, Mohamed‐Eslam F., Qian, Yuli, D'Cunha, Ronilda, Sligh, Teresa, Ferris, Laura K., Eldred, Ann, Levy, Gweneth F., Hao, Shuai, Gannu, Shashikanth, Rizzo, David G., Liu, Wei, Jazayeri, Sasha, Sofen, Howard, Carcereri De Prati, Roberto

“…Cedirogant is an inverse agonist of retinoic acid‐related orphan receptor gamma thymus (RORγt) developed for the treatment of moderate to severe chronic plaque…”
Get full text

Pharmacokinetics, Safety, and Tolerability of Cedirogant in Healthy Japanese and Chinese Adults by Mohamed, Mohamed‐Eslam F, Qian, Yuli, D'Cunha, Ronilda, Hao, Shuai, Carcereri De Prati, Roberto, Levy, Gweneth F, Hew, Kinjal, Liu, Wei

“…Cedirogant is an inverse agonist of retinoic acid‐related orphan receptor gamma, thymus (RORγt) developed for treatment of psoriasis. This study aimed to…”
Get full text

Tu1732 SAFETY OF UPADACITINIB IN ULCERATIVE COLITIS: LONG-TERM DATA FROM THE PHASE 3 OPEN-LABEL EXTENSION STUDY (U-ACTIVATE) by Panaccione, Remo, Lichtenstein, Gary R., Nakase, Hiroshi, Armuzzi, Alessandro, Kucharzik, Torsten, Levy, Gweneth, Palac, Hannah, Kujawski, Michelle, klaff, Justin, Cheon, Jae Hee

Get full text

Su1720 COMPARATIVE EFFICACY AND SAFETY OF UPADACITINIB VERSUS TOFACITINIB AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: A MATCHING-ADJUSTED INDIRECT COMPARISON by Reinisch, Walter, Tran, Jacinda N., Patel, Kamal V, Borruel, Natalia, Melmed, Gil, Wegrzyn, Lani R., Levy, Gweneth, Ilo, Dapo, Gonzalez, Yuri Sanchez, Panaccione, Remo

Get full text

Su1719 COMPARATIVE EFFICACY AND SAFETY OF UPADACITINIB VERSUS USTEKINUMAB AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: A MATCHING-ADJUSTED INDIRECT COMPARISON by Reinisch, Walter, Panaccione, Remo, Duijvestein, Marjolijn, Ceballos, Daniel, Melmed, Gil, Xuan, Si, Wegrzyn, Lani R., Levy, Gweneth, Ilo, Dapo, Gonzalez, Yuri Sanchez

Get full text

Efficacy and Safety of Upadacitinib vs Dupilumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: Week 16 results of an Open-label, Randomized, Efficacy Assessor-Blinded Head-to-Head Phase 3b/4 Study (Level Up) by Silverberg, Jonathan I, Bunick, Christopher G, Hong, H Chih-Ho, Mendes-Bastos, Pedro, Stein Gold, Linda, Costanzo, Antonio, Ibrahim, Nadia, Sancho, Cristina, Wu, Xiaoqiang, Han, Yu, Levy, Gweneth, Altman, Kathy, Calimlim, Brian, Eyerich, Kilian

“…Atopic dermatitis (AD) is a chronic skin disease characterized by intense itch and eczematous skin lesions. Some patients continue to experience flares and…”
Get full text

734 - Efficacy and safety of upadacitinib vs dupliumab in adults and adolescents with moderate-to-severe atopic dermatitis: results of an open-label, efficacy assessor-blinded head-to-head phase 3b/4 study (Level Up) by Silverberg, Jonathan I, Bunick, Christopher, Chih-ho Hong, H, Mendes-Bastos, Pedro, Gold, Linda Stein, Costanzo, Antonio, Ibrahim, Nadia, Sancho, Cristina, Wu, Xiaoqiang, Han, Yu, Levy, Gweneth, Altman, Kathy, Eyerich, Kilian

“…Abstract Introduction/Background Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by intense itch and eczematous skin lesions. Some…”
Get full text

966: EFFICACY AND SAFETY OF EXTENDED INDUCTION TREATMENT WITH UPADACITINIB 45 MG ONCE DAILY FOLLOWED BY MAINTENANCE UPADACITINIB 15 OR 30 MG ONCE DAILY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS by Vermeire, Séverine, Danese, Silvio, Zhou, Wen, klaff, Justin, Ilo, Dapo, Yao, Xuan, Levy, Gweneth, Higgins, Peter D., Loftus, Edward V., Panaccione, Remo

Get full text

533 - Long-term 5-year safety of upadacitinib in moderate-to-severe atopic dermatitis: an integrated analysis including over 7000 patient-years of exposure by Bunick, Christopher, Chovatiya, Raj, Guttman, Emma, Shahriari, Mona, Boguniewicz, Mark, Gao, Xinghua, Greiwe, Justin, Blauvelt, Andrew, Schuttelaar, Marie L A, Irvine, Alan D, Levy, Gweneth F, Platt, Andrew, Dilley, Deanne, Teixeira, Henrique, Altman, Katherine, Grada, Ayman, Silverberg, Jonathan

“…Abstract Introduction/Background Atopic dermatitis (AD) is a chronic, relapsing, inflammatory skin disease characterized by intense itch and eczematous skin…”
Get full text

Pregnancy Outcomes in Patients Treated with Upadacitinib: Analysis of Data from Clinical Trials and Postmarketing Reports by Mahadevan, Uma, Levy, Gweneth, Gensler, Lianne, Ali, Mira, Lacerda, Ana P., Wegrzyn, Lani, Palac, Hannah, Bhutani-Jacques, Tina, Long, Millie, Clowse, Megan E. B., Kimball, Alexa B., Chambers, Christina, Scialli, Anthony R.

“…Background and Objective Upadacitinib is indicated for diseases affecting persons of childbearing potential including rheumatoid arthritis, psoriatic…”
Get full text

Comparative Efficacy and Safety of Upadacitinib vs. Vedolizumab, Ustekinumab, and Tofacitinib After Induction and Maintenance for Ulcerative Colitis: Three Matching-Adjusted Indirect Comparisons by Reinisch, Walter, Melmed, Gil Y., Nakase, Hiroshi, Seidelin, Jakob, Ma, Christopher, Xuan, Si, Tran, Jacinda, Remple, Valencia, Wegrzyn, Lani, Levy, Gweneth, Sanchez Gonzalez, Yuri, Panaccione, Remo

“…Introduction Evidence on the comparative efficacy and safety of approved therapies for ulcerative colitis (UC) during induction and maintenance, including…”
Get full text

Efficacy and safety of upadacitinib for 16‐week extended induction and 52‐week maintenance therapy in patients with moderately to severely active ulcerative colitis by Panaccione, Remo, Danese, Silvio, Zhou, Wen, Klaff, Justin, Ilo, Dapo, Yao, Xuan, Levy, Gweneth, Higgins, Peter D. R., Loftus, Edward V., Chen, Su, Gonzalez, Yuri Sanchez, Leonard, Carolyn, Hébuterne, Xavier, Lindsay, James O., Cao, Qian, Nakase, Hiroshi, Colombel, Jean‐Frédéric, Vermeire, Séverine

“…Summary Background Upadacitinib is an oral, selective Janus kinase inhibitor. Aim To assess the efficacy and safety of upadacitinib in patients with…”
Get full text

Cedirogant in adults with psoriasis: a phase II, randomized, placebo-controlled clinical trial by Tyring, Stephen, Moore, Angela, Morita, Akimchi, Hong, H Chih-Ho, Song, In-Ho, Eccleston, Jason, Levy, Gweneth, Mohamed, Mohamed-Eslam F, Qian, Yuli, Wu, Tianshuang, Pan, Anqi, Hew, Kinjal, Papp, Kim A

“…Dysregulated interleukin (IL)-17/IL-23 signalling contributes to psoriasis pathogenesis. Cedirogant is an inverse agonist of nuclear receptor ROR-gamma isoform…”
Get full text

Switching from Dupilumab to Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab: Efficacy and Safety Results from the Phase 3b/4 LEVEL UP Study by Bunick, Christopher, Magnolo, Nina, Moore, Angela, Xinghua, Gao, Lynde, Charles, Ibrahim, Nadia, Grada, Ayman, Levy, Gweneth, Calimlim, Brian, Wu, Xiaoqiang, Armendariz, Yolanda, Eyerich, Kilian

“…Atopic dermatitis (AD) is a chronic skin disease characterized by intense itch and eczematous skin lesions. Upadacitinib (UPA), a selective oral Janus kinase…”
Get full text

Pharmacokinetics and Distribution of Linezolid in Cerebrospinal Fluid in Children and Adolescents by Yogev, Ram, Damle, Bharat, Levy, Gweneth, Nachman, Sharon

“…BACKGROUND:Two studies in hydrocephalic children and adolescents were performed to assess the penetration of linezolid into cerebrospinal fluid and its…”
Get full text

Observational data from the adalimumab post‐marketing PYRAMID registry of patients with Crohn's disease who became pregnant: A post hoc analysis by Hart, Ailsa, D’Haens, Geert, Bereswill, Mareike, Finney‐Hayward, Tricia, Kalabic, Jasmina, Levy, Gweneth, Liang, Huifang, Seow, Cynthia H., Loftus, Edward V., Panaccione, Remo, Reinisch, Walter, Satsangi, Jack

“…Background PYRAMID was an international post‐marketing registry that aimed to collect data on the long‐term safety and effectiveness of adalimumab treatment…”
Get full text